Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Ocean side Objections: Staggering Waterfront Breaks - 2JW Marriott Tokyo: an elegant retreat amid whirlwind of the city
- 3Lily Allen 2026 'West End Girl' arena tour: How to get tickets, prices and more
- 4A 'Stranger Things' documentary covering the final season is on its way: Watch the trailer
- 5California officials warn against foraging wild mushrooms after deadly poisoning outbreak
- Google to Use Natural Gas to Power Massive Data Center in Texas
- San Francisco sues 10 companies that make ultraprocessed food
- Extreme Manual for Purchasing Your Next Truck
- Liste des pr\u00eats qui ne n\u00e9cessitent pas de remboursement
- 'You're no longer my sister' - rows erupt as war divides Iranian families
- Vote In favor of Your #1 sort of film
- Watch SpaceX launch 119 payloads to orbit from California early on March 30
- Remote Headphones: Improve Your Sound Insight
- EU foreign ministers commemorate Russian massacre in Bucha
